Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.
Yu T, Liu X, Wu CY, Tang Z, Wang H, Schnell P, Wan Y, Wang K, Liu L, Gao Y, Sahasranaman S, Budha N.
Yu T, et al. Among authors: liu x, liu l.
Clin Transl Sci. 2024 Mar;17(3):e13769. doi: 10.1111/cts.13769.
Clin Transl Sci. 2024.
PMID: 38515348
Free PMC article.